#China #Shanghai #CAR-T therapy #Satri-cel #Jiahui International Cancer Center

A Landmark Moment in Cancer Treatment

In a groundbreaking development for oncology, Jiahui International Cancer Center (JICC) in Shanghai has welcomed its first international patient to undergo treatment with Satri-cel, the first CAR-T therapy approved globally for solid tumors. This significant milestone not only demonstrates the advancement in cancer treatments but also highlights China's growing influence in global oncology innovation.

Josh, a 59-year-old patient hailing from New Zealand, was diagnosed with advanced gastroduodenal cancer and faced dwindling treatment options in his home country. Driven by the hope of accessing innovative care, he traveled to Shanghai, where he underwent biomarker testing confirming the presence of Claudin 18.2 and the absence of HER2, making him a suitable candidate for Satri-cel, which remains exclusively available in China.

Following a comprehensive evaluation and meticulous treatment planning at JICC, Josh successfully completed the leukapheresis procedure. His CAR-T cells are currently in the manufacturing phase, with reinfusion anticipated in the coming weeks. This moment is particularly poignant as it occurs just days after China granted approval for Satri-cel, marking a revolution in cellular immunotherapy and establishing a new era in cancer treatment.

Dr. Linli Xuan, Chief of Medical Oncology at JICC, expressed the significance of this development, stating, "The approval of Satri-cel signifies a historic milestone not merely for those battling advanced gastric cancer but for the future of oncology on a global scale. We take great pride in being the first center to treat an international patient with this innovative therapy."

As the medical community witnesses escalating interest from international patients seeking cutting-edge therapies from China, JICC stands as a beacon for those seeking advanced cancer care. The center has previously treated CAR-T patients from various parts of the world, reflecting its commitment to providing innovative solutions and comprehensive support to those in need.

Jiahui International Cancer Center is renowned for its extensive spectrum of oncology services, including medical oncology, surgical oncology, radiation therapy, precision medicine, and advanced cellular therapies. Through its multidisciplinary care model equipped with an International Patient Office, JICC facilitates medical record evaluations, specialist consultations, and transition planning, ensuring seamless treatment logistics while delivering compassionate care.

As more patients around the world look towards China for advanced cancer treatments, the center aims to solidify its position as a gateway to innovative healthcare solutions. Josh's journey at JICC not only signifies personal hope but serves as an emblem of the evolving landscape in cancer therapies that are now more accessible globally.

The approval of Satri-cel marks a turning point in how advanced solid tumors are treated, paving the way for future advancements that may redefine the course of cancer care. As we progress further into this era of innovation, JICC remains dedicated to bridging gaps in patient access and bringing hope to those fighting cancer.

For further information and updates, visit Jiahui International Cancer Center.